# US Congressman Presses DOJ, DEA Heads on Cannabis Rescheduling Timeline > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-rescheduling-timeline-doj-dea-pressures/ > **Published:** 2026-03-27T14:03:49-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:36:43-04:00 > **Clinical Summary:** Explore the cannabis rescheduling timeline and its impact on federal regulation, research, and clinical practice with DOJ and DEA updates. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyResearchFederal Regulation[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)Drug Scheduling Why This Matters Cannabis rescheduling from Schedule I to Schedule III would fundamentally alter the regulatory landscape for clinical [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) and practice. This change would remove significant barriers to controlled [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and allow for more standardized pharmaceutical development pathways. Clinical Summary Congressional pressure on DOJ and DEA leadership reflects ongoing momentum toward cannabis rescheduling, specifically moving from Schedule I (no accepted medical use) to Schedule III (accepted medical use with moderate dependence potential). This regulatory shift would align federal classification more closely with current clinical evidence supporting therapeutic applications. The timeline remains uncertain, but regulatory changes of this magnitude typically require extensive review processes and stakeholder input. Dr. Caplan’s Take “While rescheduling won’t immediately change state-level [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) programs, it represents a critical step toward evidence-based policy that could accelerate legitimate research and improve patient access to standardized products.” Clinical Perspective 🧠 Clinicians should continue following existing state protocols while monitoring federal developments that may affect research opportunities and product standardization. Rescheduling could eventually improve the quality and consistency of cannabis products available to patients, though immediate clinical practice changes would be limited. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20US%20Congressman%20Presses%20DOJ%2C%20DEA%20Heads%20on%20Cannabis%20Rescheduling%20Timeline%20%40drcaplan&url=https%3A//www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15820767/us-congressman-presses-doj-dea-heads-on-cannabis-rescheduling-timeline)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15820767/us-congressman-presses-doj-dea-heads-on-cannabis-rescheduling-timeline)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20US%20Congressman%20Presses%20DOJ%2C%20DEA%20Heads%20on%20Cannabis%20Rescheduling%20Timeline%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15820767/us-congressman-presses-doj-dea-heads-on-cannabis-rescheduling-timeline)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15820767/us-congressman-presses-doj-dea-heads-on-cannabis-rescheduling-timeline](https://www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15820767/us-congressman-presses-doj-dea-heads-on-cannabis-rescheduling-timeline) Table of Contents - [FAQ](#FAQ)[What type of clinical relevance does this cannabis news have?](#What_type_of_clinical_relevance_does_this_cannabis_news_have) - [What categories does this cannabis news cover?](#What_categories_does_this_cannabis_news_cover) - [Is this information new or updated?](#Is_this_information_new_or_updated) - [Why should healthcare providers pay attention to this news?](#Why_should_healthcare_providers_pay_attention_to_this_news) - [What is the source and reliability of this information?](#What_is_the_source_and_reliability_of_this_information) - [Related](#Related) ## FAQ #### What type of clinical relevance does this cannabis news have? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” It represents emerging findings or policy developments that are worth monitoring closely by healthcare professionals. #### What categories does this cannabis news cover? The article covers multiple important areas including Policy, Research, Federal Regulation, and Medical Cannabis. This indicates it addresses both regulatory and clinical aspects of cannabis use. #### Is this information new or updated? Yes, this article is marked as “New” content from CED Clinic’s cannabis news section. It represents recent developments in the cannabis policy and research landscape. #### Why should healthcare providers pay attention to this news? The “Notable Clinical Interest” rating suggests this information could impact clinical practice or patient care. Healthcare providers should monitor these developments as they may influence treatment decisions or regulatory compliance. #### What is the source and reliability of this information? This comes from CED Clinic’s cannabis news section with a structured clinical relevance rating system. The multi-category tagging and formal rating suggest it’s curated content for healthcare professionals. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “US Congressman Presses DOJ, DEA Heads on Cannabis Rescheduling Timeline”, “url”: “https://www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15820767/us-congressman-presses-doj-dea-heads-on-cannabis-rescheduling-timeline”, “datePublished”: “2026-03-27T16:12:33Z”, “about”: “us congressman presses doj dea heads”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Rescheduling Cannabis Under the Controlled Substances Act | The Regulatory Review](https://cedclinic.com/rescheduling-cannabis-regulatory-impact/) A detailed review of the regulatory framework and implications of cannabis rescheduling under federal law. [Read the Regulatory Review](https://cedclinic.com/rescheduling-cannabis-regulatory-impact/) [Marijuana Could Be Reclassified As A Safer Drug Soon—Here’s Why – Forbes](https://cedclinic.com/marijuana-federal-rescheduling-impact-research-policy/) Insights into the potential reclassification of marijuana and what it means for safety and regulation. [Learn More on Forbes](https://cedclinic.com/marijuana-federal-rescheduling-impact-research-policy/) [Trump reclassifies state-licensed medical marijuana as less dangerous Schedule III drug](https://cedclinic.com/federal-marijuana-reclassification-clinical-research/) An overview of the historic reclassification of [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) and its regulatory impact. [Explore the Reclassification](https://cedclinic.com/federal-marijuana-reclassification-clinical-research/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).